PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 152 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $0 | -100.0% | 200 | -98.3% | 0.00% | – |
| Q2 2019 | $72,000 | +176.9% | 11,707 | +108.4% | 0.00% | – |
| Q1 2019 | $26,000 | -7.1% | 5,618 | +25.6% | 0.00% | – |
| Q3 2018 | $28,000 | +75.0% | 4,473 | +116.9% | 0.00% | – |
| Q2 2018 | $16,000 | -90.1% | 2,062 | -90.5% | 0.00% | -100.0% |
| Q1 2018 | $162,000 | +74.2% | 21,754 | +38.5% | 0.01% | +75.0% |
| Q4 2017 | $93,000 | -48.9% | 15,710 | -36.7% | 0.00% | -42.9% |
| Q3 2017 | $182,000 | +1113.3% | 24,812 | +994.0% | 0.01% | +600.0% |
| Q2 2017 | $15,000 | +275.0% | 2,268 | +338.7% | 0.00% | – |
| Q4 2016 | $4,000 | -83.3% | 517 | -86.9% | 0.00% | -100.0% |
| Q3 2016 | $24,000 | -7.7% | 3,942 | -34.5% | 0.00% | 0.0% |
| Q1 2016 | $26,000 | +23.8% | 6,018 | +71.5% | 0.00% | 0.0% |
| Q4 2015 | $21,000 | – | 3,509 | +5382.8% | 0.00% | – |
| Q3 2015 | $0 | -100.0% | 64 | -96.8% | 0.00% | -100.0% |
| Q2 2015 | $14,000 | -30.0% | 2,010 | -41.8% | 0.00% | -50.0% |
| Q1 2015 | $20,000 | – | 3,455 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
| Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
| BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
| Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
| TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
| SEARLE & CO. | 60,000 | $349,000 | 0.34% |
| TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
| Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
| TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |